A Study of MK-2060 in Healthy Participants (MK-2060-016)
A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@msd.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33147
- Advanced Pharma CR, LLC ( Site 0002)
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Alliance for Multispecialty Research, LLC ( Site 0001)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Has a body mass index (BMI) between ≥18 and ≤32 kg/m^2, inclusive
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has a history of cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Panel A: MK-2060 IV (20 minutes)
Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1.
|
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
|
|
Experimental: Panel B: MK-2060 IV (10 minutes)
Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1.
|
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
|
|
Experimental: Panel C: MK-2060 IV (5 minutes)
Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1.
|
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
|
|
Experimental: Panel D: MK-2060 IV (2.5 minutes)
Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1.
|
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
|
|
Experimental: Panel E: MK-2060 IV (1 minute)
Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1.
|
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
|
|
Placebo Comparator: Placebo
Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1.
|
Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With An Adverse Event (AE)
Time Frame: Up to 134 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
The number of participants that experience an AE will be reported.
|
Up to 134 days
|
|
Number of Participants Discontinuing the Study Due to an AE
Time Frame: Up to 134 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
The number of participants that discontinue the study due to an AE will be reported.
|
Up to 134 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC0-inf)
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-inf.
|
Predose and at designated time points post dose up to 120 days
|
|
Maximum Observed Plasma Concentration (Cmax) of MK-2060
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Cmax.
|
Predose and at designated time points post dose up to 120 days
|
|
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-168 hours.
|
Predose and at designated time points post dose up to 120 days
|
|
Plasma Concentration of MK-2060 at 168 Hours (C168)
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess C168 hours.
|
Predose and at designated time points post dose up to 120 days
|
|
Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Tmax.
|
Predose and at designated time points post dose up to 120 days
|
|
Plasma Elimination Terminal Half-life (t ½) of MK-2060
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess t½ .
|
Predose and at designated time points post dose up to 120 days
|
|
Apparent Oral Clearance (CL/F) of MK-2060
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess CL/F.
|
Predose and at designated time points post dose up to 120 days
|
|
Plasma Apparent Volume of Distribution (Vz/F) of MK-2060
Time Frame: Predose and at designated time points post dose up to 120 days
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Vz/F.
|
Predose and at designated time points post dose up to 120 days
|
|
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060
Time Frame: Baseline and up to 120 days
|
Plasma samples will be collected at baseline and pre-specified time points post-dose to assess aPTT values.
The fold change from baseline will be reported.
|
Baseline and up to 120 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2060-016
- MK-2060-016 (Other Identifier: MSD)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.